|
Pathology Codes Reminder |
|
California - Medi-Cal Providers are reminded that retroactively effective for dates of service on or after September 1, 2006, CPT-4 code 87900 (infectious agent drug susceptibility phenotype prediction using regularly updated genotypic bioinformatics) is not separately reimbursable with codes 87903 (infectious agent phenotype analysis by nucleic acid, [DNA or RNA] with drug resistance tissue culture analysis, HIV 1; first through 10 drugs tested) and 87904 (each additional drug tested). |
|
Trofile is a New Medi-Cal Benefit |
|
California - Medi-Cal Retroactive to dates of service on or after September 4, 2007, the Trofile test is a Medi-Cal benefit and can be billed using CPT-4 code 87999 (unlisted microbiology procedure). Current Medi-Cal reimbursement for this code is “By Report.” This blood test is available for recipients with diagnosed Acquired Immune Deficiency Syndrome (AIDS) who have evidence of viral replication and HIV-1 strain resistance to multiple anti-retroviral agents. This test will help determine if the recipient will respond to a new class of drugs, classified as CCR-5 antagonists. This test is to be performed only once in the recipient’s lifetime. Providers must document on the claim that the recipient has evidence of anti-retroviral drug resistance intolerance and a lack of patient acceptability to reasonable alternative anti-retroviral drug regimens resulting in inability to fully suppress HIV. Failure to provide such documentation will result in denial of the claim. |
|
AmniSure Test Not a Medi-Cal Benefit |
|
California - Medi-Cal Providers are reminded that the AmniSure test for detecting amniotic fluid in female recipients is not a Medi-Cal benefit. Providers may not bill for this test using any CPT-4 80000 series laboratory procedure codes, including CPT-4 codes 83518 (immunoassay for analyte other than infectious agent antibody or infectious agent antigen, qualitative or semiquantitative; single step method [eg, reagent strip]) and 84999 (unlisted chemistry procedure). |
|
CPT-4 Codes 80061 and 83721 Billing and Reimbursement Update |
|
California - Medi-Cal Effective for dates of service on or after May 1, 2008, CPT-4 codes 80061 (lipid panel test) and 83721 (LDL cholesterol test) may not both be reimbursed on the same date of service, for the same recipient, and by the same rendering provider unless the triglyceride level of the recipient is greater than 400 mg/dl. This triglyceride level value must be entered in the Remarks field (Box 80)/Reserved for Local Use field ( Box 19) of the claim form. In addition, both CPT-4 codes must be billed on the same claim form in order for providers to receive reimbursement for codes 80061 and 83721 on the same date of service. If the triglyceride level of the recipient is less than 400 mg/dl and both CPT-4 codes 80061 and 83721 are billed on the same date of service, for the same recipient, and by the same rendering provider, only code 80061 will be reimbursed. |
|
Billing Requirement Update for CPT-4 code 88141 |
|
California - Medi-Cal Effective on or after May 1, 2008, reporting for CPT-4 code 88141 (cytopathology, cervical, or vaginal [any reporting system] requiring interpretation by physician) has been updated. A pathology report is no longer required. Claims billing CPT-4 code 88141 may now be reimbursed if the patient has recently had an abnormal Papanicolaou smear and the claim is billed with ICD-9-CM diagnosis codes 795.0 – 795.09. Failure to document one of these ICD-9-CM diagnosis codes will result in denial of the claim. |
|
Family PACT Billing Update for CPT-4 Code 88141 |
|
California - Medi-Cal Effective for dates of service on or after May 1, 2008, claims billed with CPT-4 Code 88141 (cytopathology, cervical, or vaginal [any reporting system] requiring interpretation by physician) no longer require a pathology report copy for manual review, and may now be reimbursed when billed with a primary and secondary diagnosis code. Providers should submit claims for code 88141 using a primary diagnosis S-code and a secondary ICD-9-CM diagnosis code within the range of 795.0 – 795.09. Claims will be denied unless they include both an acceptable S-code in the primary diagnosis field and a valid secondary diagnosis code. |
|
Reminder: End-Dating of Medi-Cal Provider Numbers |
|
California - Medi-Cal Providers are reminded that once a claim is submitted with a National Provider Identifier (NPI), the associated Medi-Cal “legacy” provider number(s) will be end-dated. In other words, effective for dates of service beyond the date of a claim submitted with an NPI, the Medi-Cal provider number will no longer be valid. Using the associated Medi-Cal provider number(s) following a claim submission with an NPI will result in claim denials for subsequent dates of service. Once providers begin using their NPI on claim submissions, they are strongly encouraged to continue using the NPI to prevent claim payment interruption. |
|
New CLIA Waived Tests |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
CMS
New waived tests and their effective dates. The CPT codes for these tests must have the QW modifier to be recognized as a waived test.
The following CPT codes do not require the QW modifier in order to be recognized as waived tests:
|
|
RARC and CARC Update |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
CMS
Modified Codes
Deactivated Codes
Claim Adjustment Reason Codes New Codes
Modified Codes
Deactivated Codes
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Collapsing Medicare Provider Transaction Access Numbers (PTANs) to Ensure a One-to-One National Provider Identifier (NPI) Match |
|||
|
CMS
CMS issued CR 5906 because it believes that providers may want to collapse their assigned Medicare PTANs to insure a one-to-one NPI match. Providers may collapse PTANs that are assigned to additional locations only if the additional locations are all assigned the same tax identification number (TIN) and are within the same pricing locality. Presently, some Medicare carriers issue separate PTANs to physicians with multiple practice locations. To ensure that carriers are assigning PTANs in a more consistent manner and to aid in the implementation of the NPI, carriers and A/B MACs will assign the minimum number of PTANs necessary to ensure that proper payments are made. Providers can request their carrier or A/B MAC collapse their PTANs by submitting a letter on their letterhead to the Medicare contractor. The letter must contain:
|
|
Healthcare Common Procedure Coding System (HCPCS) Codes Subject to and Excluded from Clinical Laboratory Improvement Amendments (CLIA) Edits |
|||||||||||||||||||||||||
|
CMS
CR 5926 informs carriers and A/B MACS about the new HCPCS codes for 2008 that are subject to CLIA edits and also about those that are now excluded from CLIA edits. The HCPCS codes listed in the chart that follows are new for 2008 and are subject to CLIA edits.
|
|
REVISED ABN NOTICE |
||
|
CMS
On Monday, March 3, 2008, CMS will implement use of the revised Advance Beneficiary Notice of Noncoverage (ABN) (CMS-R-131). This form replaces the General Use ABN (CMS-R-131-G), and the Lab ABN (CMS-R-131-L) for physician ordered laboratory tests. The form and notice instructions will be posted on the Beneficiary Notice Initiative web page (http://www.cms.hhs.gov/BNI/02_ABNGABNL.asp#TopOfPage). Updated manual instructions and the Spanish version of the form on the BNI web page will be posted in the near future. Some key features of the new form are that it:
CMS will allow a 6-month transition period from the date of implementation for use of the revised form and instructions. Thus, all providers and suppliers must begin using the new ABN (CMS-R-131) no later than September 1, 2008. Questions about the new ABN may be sent to RevisedABN_ODF@cms.hhs.gov |
|
Clinical Laboratory Fee Schedule - Implementation of Section 113 Medicare, Medicaid and State Children’s Health Insurance Program (MMSCHIP) Legislation |
|||
|
CMS
Change Request (CR) 5987 alerts clinical laboratories that, effective for tests furnished on or after April 1, 2008, the MMSCHIP Extension Act of 2007 sets payment for code 83037 and 83037QW (Hemoglobin; glycosylated (A1c) by device) by crosswalking it to be the same as 83036 (glycosylated (A1c)). The payment be the same as the payment on the clinical laboratory fee schedule for 83036. |
|
|
||
| Contact Us | Privacy Statement | Legal | ||
| ©2008 XIFIN®, Inc. All rights reserved. | ||